Voluntary Site of Service Management Policy
Customize your policy alerts
Sign up for blue cross blue shield - alabama Policy PH-9001 alerts
Get alerted when Policy PH-9001 changes without checking for updates manually.
Monitor payer policy activity
This policy governs voluntary management of site of care for members receiving select infused specialty medications, enabling transition from higher‑cost hospital outpatient settings to more cost‑effective alternate infusion locations when clinically appropriate. It applies to members and providers participating in the Provider‑Administered Drug Program with home health benefits.
No material clinical or coverage changes in this revision.
Coverage Criteria
Voluntary Site‑of‑Service Transition Criteria
Covered when ALL of the following are met
IRC confirms these criteria prior to transition
Member Identification
Members will be managed when ANY of the following apply
Identification through prior authorization program or paid claims reporting
Certain agents in the drugs‑in‑scope listing are specifically annotated for use only in non‑oncology diagnoses. For example, rituximab entries (J9312 and biosimilar/Q‑codes such as Q5119 and Q5115) are listed with the parenthetical note “non‑oncology diagnosis only.” This indicates that site‑of‑service management under this program applies to rituximab when used for non‑oncology indications, and oncology uses are outside the scope of the Voluntary Site‑of‑Service Management program for those codes.
Drugs in Scope / Coding
| J3262 | ACTEMRA / tocilizumab |
| J0791 | ADAKVEO / crizanlizumab-tmca |
| J1931 | ALDURAZYME / laronidase |
| J1554 | ASCENIV / intravenous immune globulin |
| Q5121 | AVSOLA / infliximab-axxq |
| J0490 | BENLYSTA / belimumab |
| J0597 | BERINERT / C1 esterase inhibitor |
| J1556 | BIVIGAM / intravenous immune globulin |
| J1786 | CEREZYME / imiglucerase |
| J0717 | CIMZIA / certolizumab pegol |
| J1569 | intravenous immune globulin |
| J1566 | GAMMAGARD S/D, CARIMUNE NF / intravenous immune globulin |
| J1561 | GAMMAKED / intravenous immune globulin |
| J1557 | GAMMAPLEX / intravenous immune globulin |
| J1561 | GAMUNEX / intravenous immune globulin |
| J1599 | IMMUNE GLOBULIN / intravenous immune globulin |
| Q5103 | INFLECTRA / infliximab-dyyb |
| J2840 | KANUMA / sebelipase alfa |
| J0221 | LUMIZYME / alglucosidase alfa |
| J1458 | NAGLAZYME / galsulfase |
| Q5104 | infliximab-abda |
| J9312 | RITUXAN / rituximab ( non-oncology diagnosis only ) |
| Q5119 | RUXIENCE / rituximab-pvvr ( non-oncology diagnosis only ) |
| J1299 | SOLIRIS / eculizumab |
| J3357 | STELARA / ustekinumab |
| J3241 | TEPEZZA / teprotumumab-trbw |
| J2356 | TEZSPIRE / tezepelumab-ekko |
| J1746 | TROGARZO / ibalizumab-uiyk |
| Q5115 | TRUXIMA / rituximab-abbs ( non-oncology diagnosis only ) |
| J2323 | TYSABRI / natalizumab |
Provider Actions and Authorization
Prior Authorization and Transition
All drugs in the Voluntary Site of Service Management require prior authorization. Members will be identified through the Provider-Administered Drug prior authorization program or through paid claims reporting for current utilizers. Members with approved drug prior authorizations who are identified as receiving listed specialty drugs in a hospital outpatient setting will be transitioned internally to Prime Therapeutics' Infusion Referral Center (IRC) for potential movement to an alternate site of care.
- All drugs in the Voluntary Site of Service Management require prior authorization
- Members identified via PA program or paid claims reporting
- Transition to Prime Therapeutics' IRC for members receiving listed specialty drugs in hospital outpatient setting
Provider Actions
Providers must coordinate with the IRC and the member's prescriber to facilitate any transition of infusion services. The provider should ensure eligibility of benefits, obtain required approvals, and supply clinical information requested by IRC to support the transition.
- Contact IRC to initiate transition workflow
- Confirm prescriber agreement and clinical appropriateness for alternate site of treatment
- Provide clinical documentation and respond to IRC requests in a timely manner
Nursing Precertification
When required by the member's benefits, the home infusion provider is responsible for obtaining all necessary nursing precertifications prior to initiation of home infusion services.
- Home infusion provider obtains nursing precertifications as specified by member benefits
- Precertification must be secured before home infusion services begin to avoid delays or denials
Prior Authorization Required
Lack of required prior authorization may result in the member not being identified for transition, denial of payment, or other impacts to coverage and site-of-care management. Providers should verify PA approval before administering or billing for services.
- Absence of PA can prevent identification for transition to IRC
- Services provided without PA may be denied or subject to retrospective review
- Verify prior authorization status before scheduling or delivering infusion services
Definitions
Site of Care Transition
Offer transition from hospital outpatient to more cost‑effective alternate setting
Members receiving select infused specialty medications in a hospital outpatient setting will be offered transition to a more cost‑effective alternate site of care (for example, home infusion or another outpatient setting) when they have sufficient home health benefits and both the member and prescriber agree; the IRC coordinates the transition.
- IRC confirms member eligibility, member and prescriber agreement, and clinical appropriateness before effectuating transition.
Background
The Voluntary Site‑of‑Service Management program identifies members receiving select infused specialty medications in higher‑cost hospital outpatient settings and offers to transition eligible members to more cost‑effective alternate infusion locations (for example, home infusion or other outpatient sites). The program is intended to preserve clinical appropriateness while reducing site‑of‑care costs by coordinating transitions when members have adequate home health benefits and both the member and prescriber agree.
Operationally, members are identified through the Provider‑Administered Drug prior authorization process or via paid claims reporting and then referred to Prime Therapeutics' Infusion Referral Center (IRC) for coordination. The IRC confirms member eligibility, obtains prescriber and member agreement, and verifies clinical appropriateness before managing the transition.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.